Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:35 AM
Ignite Modification Date:
2025-12-25 @ 4:35 AM
NCT ID:
NCT04080518
Eligibility Criteria:
Inclusion Criteria:
1. Diagnosis of heart failure NYHA stage I or II - as shown by their medical records
2. Stable anti-hypertensive treatment (\>4 weeks)
3. Male and female patients older than 21 years
4. Willingness to participate and ability to provide informed consent
5. Willingness to use effective birth control if of childbearing potential. Any kind of contraception method will be allowed for the period of the study
Exclusion Criteria:
1. Patients with congestive heart failure NYHA stages I (LVEF \>40%) without type 2 diabetes mellitus.
2. Patients with congestive heart failure NYHA stages III and IV
3. Prior serious hypersensitivity reaction to Dapagliflozin (Forxiga®)
4. Treatment with any SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitors within 1 week prior to Visit 1 or during screening period until Visit 1
5. Pregnant and breast-feeding women
6. Diagnosis of type 1 diabetes mellitus
7. Patients with type 2 diabetes mellitus with HbA1C \> 10.5% from most recent medical records or antidiabetic therapies other than metformin, sulfonylureas or gliptins at screening.
8. Patients with type 2 diabetes mellitus whose antidiabetic treatment (metformin and/or sulfonylureas and/or gliptins) has been changed or unstable within 6 weeks prior to Visit 1
9. . Unstable or rapidly progressing renal disease
10. Chronic cystitis and recurrent urinary tract infections
11. Impaired renal function with eGFR\<45 ml/min/1.73m2 or proteinuria \> 0.5 g/24h
12. Severe hepatic impairment (Child-Pugh class C)
13. Any major cardiovascular event/vascular disease within 3 months prior to enrolment, as assessed by the investigator
14. Severe edema (as judged by the investigator)
15. Active cancer, history of bladder cancer
16. HIV infection
17. Patients who have received an organ or bone marrow transplant
18. Patients who have had major surgery in the past 3 months
19. Patients who have severe comorbid conditions likely to compromise survival or study participation
20. Patients who exhibit noticeable anxiety and/or claustrophobia or who exhibit severe vertigo when they are moved into the MRI scanner
21. Patients with exclusion criteria for the MRI, such as:
1. implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear implants)
2. iron-based tattoos
3. any other pieces of metal or devices that are not MR-Safe anywhere in the body
22. Unwillingness or other inability to cooperate
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
21 Years
Study:
NCT04080518
Study Brief:
Protocol Section:
NCT04080518